M6620 was well tolerated in combination with carboplatin chemotherapy at biologically active doses, with the observation of clinical activity in patients with advanced solid tumors, including a patient with platinum-refractory and PARP inhibitor–resistant germline BRCA1 ovarian cancer. Here, BRCA1 is linked to ovarian carcinoma.